SCHEMBL2642338

SCHEMBL2642338

CN(C)S(=O)(=O)c1cccc(Cl)c1Cl

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 1/20 0.67
ALDH1A1 P00352 5/20 0.47
TSHR P16473 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HTT P42858 1/20 0.46
HSD11B1 P28845 1/20 0.46
POLB P06746 2/20 0.45
LMNA P02545 2/20 0.43
KMT2A Q03164 1/20 0.43
GSTO1 P78417 2/20 0.42
PTGES2 Q9H7Z7 1/20 0.42
AKR1B1 P15121 1/20 0.41
GLA P06280 1/20 0.41
PGR P06401 1/20 0.41
CCR4 P51679 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229460 0.83 PGR (0.54) MCOLN3ALDH1A1SMN1; SMN2HTTHSD11B1
SCHEMBL17442030 0.81 CYP1A2 (0.48) MCOLN3ALDH1A1TSHRSMN1; SMN2HTT
SCHEMBL7847967 0.79 MCOLN3 (0.56) MCOLN3ALDH1A1TSHRHSD11B1LMNA
SCHEMBL12010352 0.79 MCOLN3 (0.56) MCOLN3ALDH1A1TSHRHSD11B1LMNA
SCHEMBL17760483 0.78 MCOLN3 (0.55) MCOLN3ALDH1A1TSHRHSD11B1LMNA
SCHEMBL10727766 0.78 ALDH1A1 (0.45) MCOLN3ALDH1A1TSHRSMN1; SMN2HTT
SCHEMBL4033271 0.78 MCOLN3 (0.55) MCOLN3ALDH1A1TSHRHSD11B1KMT2A
SCHEMBL2633428 0.77 MCOLN3 (0.53) MCOLN3TSHRHSD11B1LMNAKMT2A
SCHEMBL10455037 0.77 MCOLN3 (0.54) MCOLN3ALDH1A1TSHRSMN1; SMN2HTT
SCHEMBL4027618 0.77 MCOLN3 (0.54) MCOLN3ALDH1A1TSHRHSD11B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK MCOLN3 4156/4885ALDH1A1 1558/4885TSHR 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.